105906-07-8Relevant articles and documents
Synthetic method for 4-tertiary butyl cyclohexaneacetic acid
-
Paragraph 0021, (2016/10/10)
The invention provides a synthetic method for 4-tertiary butyl cyclohexaneacetic acid. The synthetic method comprises the steps of: firstly adding sodium hydride into dried tetrahydrofuran; stirring the mixture and reducing the temperature to 0 DEG C; adding triethyl phosphonoacetate and stirring the mixture; adding a tetrahydrofuran solution of 4-tertiary butyl cyclohexanone, and raising the temperature to room temperature and stirring the mixture; then adding obtained 4-tertiary butyl ethyl cyclohexylideneacetate into methanol; then adding raney nickel to react in a hydrogen atmosphere; and finally mixing the 4-tertiary butyl ethyl cyclohexylacetate with an aqueous solution of sodium hydroxide, and heating and stirring the mixture to obtain the 4-tertiary butyl cyclohexaneacetic acid. The method provides the effective method for producing the 4-tertiary butyl cyclohexaneacetic acid. The method is few in step, high in yield, simple in post-treatment such as purification and easy for industrial production and operation.
Cycloalkylamides and their therapeutic applications
-
, (2008/06/13)
The present invention relates to the use of compounds of formula (I) for the treatment of a variety of disorders including, but not limited to, epilepsy, bipolar disorder, psychiatric disorders, migraine, pain, neuroprotection, and movement disorders.
Cycloalkylamides and their therapeutic applications
-
, (2008/06/13)
The present invention relates to the use of compounds of formula (I) for the treatment of a variety of disorders including, but not limited to, epilepsy, bipolar disorder, psychiatric disorders, migraine, pain, neuroprotection, and movement disorders.
Metalloproteinase inhibitors
-
, (2008/06/13)
PCT No. PCT/GB96/02877 Sec. 371 Date May 22, 1998 Sec. 102(e) Date May 22, 1998 PCT Filed Nov. 21, 1996 PCT Pub. No. WO97/19053 PCT Pub. Date May 29, 1997Compounds of general formula (I) wherein X ia a -CO2H, -NH(OH)CHO or -CONHOH group; R1 is a cylcoalkyl, cycloalkenyl or non-aromatic heterocyclic ring containing up to 3 heteroatoms, any of which may be (i) substituted by one ore more substituents selected from C1-C6 alkyl, C2-C6 alkenyl, halo, cyano (-CN), -CO2H, -CO2R, -CONH2, -CONHR, -CON(R)2, -OH, -OR, oxo-, -SH, -SR, -NHCOR, and -NHCO2R wherein R is C1-C6 alkyl or benzyl and/or (ii) fused to a cycloalky or heterocyclic ring; and R2, R3, R4 and R5 are as defined in specification are matrix metalloproteinase inhibitors.
SYNTHESIS OF CYCLOHEXYLALIPHATIC ACIDS AND THEIR PHARMACOLOGICAL PROPERTIES
Kuchar, Miroslav,Brunova, Bohumila,Grimova, Jaroslava,Vanecek, Stanislav,Holubek, Jiri
, p. 2896 - 2908 (2007/10/02)
A series of substituted cyclohexylacetic acids I has been obtained by hydrogenation of the unsaturated analogues II and III.Esters of these analogues were prepared by the Horner-Wittig reaction of the corresponding cyclohexanones IV and/or 2-cyclohexenones V with triethyl phosphonoacetate.These esters were obtained in two isomeric forms (Z and E), differing in the double bond in the exo-position.The derivatives with a substituent in the 2-position exhibited a partial shift of the double bond to the cyclohexane ring; this shift was especially marked in the 2-phenyl derivative.With the acids I-III, activation of fibrinolysis was assessed by the hanging clot method; the anti-inflammatory effect was assessed by inhibition of two experimental model inflammations.The regression equation relating fibrinolytic capacity to lipophilicity was a quadratic one, the logarithm of optimum lipophilicity being log Popt = 5.55.A qualitative assessment of the anti-inflammatory effect in relation to lipophilicity suggests that log Popt is probably higher than with arylaliphatic acids.These acids seem to have an active site different from that of the acids I-III.
Antiprotozoal compounds
-
, (2008/06/13)
1,4-Naphthoquinones of formula (I), methods for their preparation, veterinary formulations thereof, and the use thereof in animal therapy are disclosed. STR1 Particularly preferred compounds of formula (I) are, 2-[trans-(4-t-butylcyclohexyl)methyl]-3-hydroxy-1,4-naphthoquinone, and 2-[trans-(4-t-pentyl cyclohexyl)methyl]3-hydroxy-1,4-naphthoquinone. The compounds are of value as anti-protozoal agents, in particular as anti-theilerial agents.
Stereochemistry of 1,4-Addition of Nucleophiles to Ethyl Cyclohexylidenecyanoacetates
Nasipuri, Dhanonjoy,Sarkar, Ashis,Konar, Samir K.
, p. 2840 - 2845 (2007/10/02)
The stereochemistry of 1,4-addition of several nucleophiles such as cyanide, sodium borohydride, and methylmagnesium iodide to three substituted ethyl cyclohexylidenecyanoacetates (1-3) has been determined.A higher preference for equatorial attack is observed in these compounds than in related cyclohexanones, which is considerably diminished by the use of aprotic polar solvents.The results do not show any appreciable contribution of product stability control, recently shown to be important for hydride reduction of cyclohexanones, and have been rationalized on thebasis of a six-center cyclic transition state in which steric factors play a dominant role.These compounds have also been reduced by catalytic hydrogenation (Pd/C), and, interestingly, with unhindered systems (1, 2) hydrogenation takes place more from the axial side (40-60percent) as compared to cyclohexanones.
